News | Prostate Cancer | July 15, 2016

Photoacoustic Imaging Is Promising Option for Noninvasive Monitoring of Prostate Cancer

Imaging technology may lead to better monitoring of prostate tumors and treatment decision-making

photoacoustic imaging

Images of prostate cells captured through photoacoustic imaging. Top: cancer cells that express the targeted cancer marker, PSMA; bottom: cells that lack PSMA. A research team led by Kent Nastiuk of Roswell Park Cancer Institute has published new evidence that this approach can be a useful tool in monitoring and selecting treatments for many cancers.

While active surveillance is often recommended for patients with nonaggressive prostate cancer to reduce unnecessary treatment, the challenge for clinicians is to monitor and distinguish early-stage tumors from advanced cancers. A team of scientists led by researchers from Roswell Park Cancer Institute have demonstrated that photoacoustic imaging (PAI) may be an effective tool for more accurately viewing and monitoring prostate cancer. The new research has been published in the June 2016 issue of the Journal of Biomedical Optics.

Photoacoustic imaging is an emerging noninvasive imaging modality that has not yet been used in clinical settings. Using photoacoustic imaging, this team of scientists focused a laser light on prostate cells and then “listened” using ultrasound technology to see how a dye attached to a specific prostate cancer marker, PSMA, reacted to the light waves. They chose to study this technology’s use in imaging prostate cancer, as the prostate can be imaged in situ. Photoacoustic imaging of these prostate cells, the researchers found, enabled good discrimination between cells with and without the cancer marker.

“This proof-of-concept study demonstrates that this technology may allow for real-time monitoring of prostate cancer in patients during the course of active surveillance. For patients with more aggressive disease, the technology could offer more precise targeting of biopsies to confirm the need for definitive therapy,” said senior author of the study Kent Nastiuk, Ph.D., assistant professor of cancer genetics and genitourinary cancers at Roswell Park. “This technology offers the potential to confirm the initial prostate cancer diagnosis, guide biopsies and monitor tumor volume — which is currently not measureable — for improved case management and treatment decision-making.”

Nastiuk’s co-authors include scientists from Roswell Park Cancer Institute, the University of Rochester and the Rochester Institute of Technology.

The study, “Photoacoustic Imaging with an Acoustic Lens Detects Prostate Cancer Cells Labeled with PSMA-targeting Near Infra-red Dye-conjugates,” is available at biomedicaloptics.spiedigitallibrary.org.

This work was supported by the National Cancer Institute (project nos. R01CA151753, R15CA192148 and P30CA16056), National Institute of Biomedical Imaging and Bioengineering (project no. R15EB019726), National Institute of Arthritis and Musculoskeletal and Skin Diseases (project no. P30AR061307), the U.S. Department of Defense (award no. W81XWH-14-1-0242) and the Sonya A. Sinicki Foundation for Cancer Research (award 615SF).

 

Related Content

Acuson Sequoia
News | Ultrasound Imaging | September 12, 2018
Siemens Healthineers announced the first global installation of its newest ultrasound system, the...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
Mount Sinai Serves as Official Medical Services Provider for 2018 U.S. Open
News | Orthopedic Imaging | September 06, 2018
For the sixth consecutive year, Mount Sinai will serve as the official medical services provider for the 2018 U.S. Open...
Konica Minolta Provides Sonimage HS1 Ultrasound for AAPM&R Hands-on Learning Course
News | Ultrasound Imaging | September 05, 2018
Konica Minolta Healthcare Americas recently provided ultrasound systems for The American Academy for Physical Medicine...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...
Overlay Init